Compare BZH & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZH | REPL |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 717.3M | 721.7M |
| IPO Year | 1994 | 2018 |
| Metric | BZH | REPL |
|---|---|---|
| Price | $22.54 | $10.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $32.00 | $12.00 |
| AVG Volume (30 Days) | 504.8K | ★ 1.7M |
| Earning Date | 01-29-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.52 | N/A |
| Revenue | ★ $2,371,555,000.00 | N/A |
| Revenue This Year | $7.40 | N/A |
| Revenue Next Year | $12.09 | N/A |
| P/E Ratio | $14.82 | ★ N/A |
| Revenue Growth | ★ 1.77 | N/A |
| 52 Week Low | $17.37 | $2.68 |
| 52 Week High | $32.21 | $14.80 |
| Indicator | BZH | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 51.90 | 61.36 |
| Support Level | $21.50 | $9.35 |
| Resistance Level | $23.21 | $11.09 |
| Average True Range (ATR) | 0.80 | 0.60 |
| MACD | 0.09 | -0.08 |
| Stochastic Oscillator | 60.56 | 53.32 |
Beazer Homes USA Inc is an construction company that focuses on residential construction. The company specializes in single-family housing and multi-unit building construction in over 13 states and over 22 metro markets. Beazer Homes builds homes and communities that target first-time, move-up, and luxury homebuyers with an average selling price of roughly $300,000. From a geographic perspective, home sales in the western and eastern United States have been the leading sources of revenue for the company. Key metro areas include Atlanta, Las Vegas, Los Angeles, Orlando, and Tampa. The company also focuses on land purchasing and development to support future construction efforts as well as mortgage services for its homebuyers.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.